Bioxcel Therapeutics: HC Wainwright Raises PT to $10, Reiterates Buy Rating

Bioxcel Therapeutics: HC Wainwright Raises PT to $10, Reiterates Buy Rating

Bioxcel Therapeutics (NASDAQ: BTAI) has seen a positive development in its stock price following the 27th Annual Global Investment Conference hosted by H.C. Wainwright. The investment firm has raised its price target (PT) to $10, reiterating its buy rating for the company BioXcel Therapeutics at H.C. Wainwright: Expanding IGALMI’s Reach^[1].

During the conference, BioXcel Therapeutics presented its strategic focus on expanding IGALMI, a treatment for agitation in schizophrenia and bipolar disorder. The company highlighted the promising potential of IGALMI in home settings, despite challenges in commercialization and regulatory steps ahead.

Key takeaways from the presentation include the expansion of IGALMI's use to home settings, targeting a larger market. The SERENITY At-Home trial showed IGALMI's safety in a home setting, and an sNDA for IGALMI's home use is expected in Q1 2026. Additionally, BioXcel is pursuing an Alzheimer’s agitation treatment, with a second Phase 3 trial planned. The company aims to address 57 to 77 million agitation episodes, up from 23 million.

Operational updates include the completion of the SERENITY At-Home safety trial involving 200 patients, alignment with the FDA on sNDA content and format in August, and the development of a commercial strategy for potential 2026 approval of IGALMI in home settings. An agreement with the FDA for the Alzheimer’s program is also in place, with CRO evaluations underway.

Looking forward, the filing of the sNDA for IGALMI in home settings is planned for Q1 2026. Ongoing efforts to define commercialization strategies for both in-care and home settings are in progress. A second confirmatory Phase 3 trial for Alzheimer’s agitation is planned, and the presentation of SERENITY At-Home trial data at upcoming scientific conferences is anticipated.

Vimal Mehta, CEO of BioXcel Therapeutics, emphasized the company's mission to develop transformative medicines in neuroscience utilizing artificial intelligence platforms. He highlighted the rapid development of IGALMI, which was approved in 3.5 years from the first clinical trial to market. Mehta also discussed the broader market potential of the company's drug, which can help in various stress-related neuropsych conditions.

The investment firm's positive outlook on BioXcel Therapeutics is based on the company's strong pipeline, positive clinical data, and the large unmet medical need for agitation treatment in both in-care and home settings.